Caladrius Biosciences, Inc. (CLBS)
CLBSPrice: $0.43
Fair Value: 🔒
🔒score
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II ... more
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and c... more
Description
Shares
| Market Cap | $3.35M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David Mazzo |
| IPO Date | 1995-11-03 | CAGR | -0.04% |
| Employees | 27 | Website | www.caladrius.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CLBS chart loading...
Fundamentals
Technicals
| Enterprise Value | $-13.17M | P/E Ratio | -1.08 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 16.86 | P/B Ratio | 1.04 |
| P/CF Ratio | -1.04 | P/FCF Ratio | -1.05 |
| EPS | $-0.39 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 0.96% |
| Operating Margin | -14.64% | Profit Margin | -17.05% |
| ROE | -0.78% | ROA | -0.84% |
| ROCE | -0.91% | Current Ratio | 4.72 |
| Quick Ratio | 4.72 | Cash Ratio | 4.16 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -34.81 | Piotroski Score | 3 |